Search Within

Isabelle C Riviere

  1. "Blood"
  2. "Xiuyan Wang"
  3. "Hematologic Malignancies Research"
  4. "Yvette Bernal"
Formats
  1. Meeting Abstract (10)
  2. Journal Article (2)
Groups
  1. Adult Leukemia (12)
  2. Center for Hematologic Malignancies (12)
  3. Department of Medicine (12)
  4. GSK Faculty (12)
  5. Hematologic Malignancies Research (12)
  6. Hematologic Malignancies, Division of (12)

More Groups

People
  1. Jae Park (12)
  2. Renier Brentjens (12)
  3. Xiuyan Wang (12)
  4. Yvette Bernal (12)
  5. Michel Sadelain (10)
  6. Elizabeth Halton (8)

More People

Years
  1. 2019 (2)
  2. 2018 (2)
  3. 2017 (1)
  4. 2015 (1)
  5. 2014 (2)
  6. 2013 (2)

More Years

Publications
  1. Blood (12)
Publishers
  1. American Society of Hematology (12)

Results (12)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical factors associated with improved survival following allogeneic HSCT after CD19 CAR therapy in adult patients with relapsed B-ALL
    Meeting Abstract

    Park, J. H.; Flynn, J.; Gonen, M.; Bernal, Y.; Diamonte, C.; Halton, E.; Wang, X.; Riviere, I.; Sadelain, M.; Brentjens, R. J.
    Blood (2019)

    Fulltext@MSK | Save
  • CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma
    Journal Article

    Sauter, C. S.; Senechal, B.; Rivière, I.; Ni, A.; Bernal, Y.; Wang, X.; Purdon, T.; Hall, M.; Singh, A. N.; Szenes, V. Z.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A phase I first-in-human clinical trial of CD19-targeted 19-28z/4-1BBL "armored" CAR T cells in patients with relapsed or refractory NHL and CLL including Richter's transformation
    Meeting Abstract

    Park, J. H.; Palomba, M. L.; Batlevi, C. L.; Riviere, I.; Wang, X.; Senechal, B.; Furman, R. R.; Bernal, Y.; Hall, M.; Pineda, J.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Clinical responses and pharmacokinetics of MCARH171, a human-derived BCMA targeted CAR T cell therapy in relapsed/refractory multiple myeloma: Final results of a phase I clinical trial
    Meeting Abstract

    Mailankody, S.; Ghosh, A.; Staehr, M.; Purdon, T. J.; Roshal, M.; Halton, E.; Diamonte, C.; Pineda, J.; Anant, P.; Bernal, Y.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Development and evaluation of a human single chain variable fragment (scFv) derived BCMA targeted CAR T Cell vector leads to a high objective response rate in patients with advanced MM
    Meeting Abstract

    Smith, E. L.; Mailankody, S.; Ghosh, A.; Masakayan, R.; Staehr, M.; Purdon, T. J.; Halton, E.; Diamonte, C.; Anant, P.; Bernal, Y.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Implications of minimal residual disease negative complete remission (MRD-CR) and allogeneic stem cell transplant on safety and clinical outcome of CD19 targeted 19-28z CAR modified T cells in adult patients with relapsed, refractory B-cell ALL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X. Y.; Bernal, Y.; Purdon, T.; Halton, E.; Wang, Y.; Curran, K. J.; Sauter, C. S.; Sadelain, M.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Interim safety analysis: A phase I trial of high dose therapy and autologous stem cell transplantation followed by infusion of chimeric antigen receptor modified T-cells (19-28z CAR-T) directed against CD19+B-cells for relapsed and refractory aggressive B cell non-Hodgkin lymphoma (B-NHL)
    Meeting Abstract

    Sauter, C. S.; Riviere, I.; Bernal, Y. J.; Wang, X. Y.; Purdon, T. J.; Yoo, S.; Moskowitz, C. H.; Giralt, S.; Matasar, M. J.; Curran, K. J.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • CD19-targeted 19-28z CAR modified autologous T cells induce high rates of complete remission and durable responses in adult patients with relapsed, refractory B-cell ALL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X. Y.; Bernal, Y. J.; Yoo, S.; Purdon, T.; Halton, E.; Quintanilla, H.; Curran, K. J.; Sauter, C. S.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Phase I trial of autologous CD19-targeted CAR-modified T cells as consolidation after purine analog-based first-line therapy in patients with previously untreated CLL
    Meeting Abstract

    Park, J. H.; Rivière, I.; Wang, X.; Stefanski, J.; He, Q.; Borquez-Ojeda, O.; Wasielewska, T.; Taylor, C.; Qu, J.; Bartido, S.; more...
    Blood (2013)

    Fulltext@MSK | Save
  • Safe and effective re-induction of complete remissions in adults with relapsed B-ALL using 19-28z CAR CD19-targeted T cell therapy
    Meeting Abstract

    Davila, M. L.; Riviere, I.; Wang, X.; Bartido, S.; Stefanski, J.; He, Q.; Borquez-Ojeda, O.; Taylor, C.; Wasielewska, T.; Qu, J.; more...
    Blood (2013)

    Fulltext@MSK | Save